This 2021 systematic review evaluated the efficacy of hormone maintenance therapy (HMT) following cytoreductive surgery in women with low-grade serous ovarian cancer (LGSOC). Four cohort studies encompassing 558 patients (127 receiving HMT) were analyzed. The studies exhibited significant heterogeneity in HMT regimens, dosing, and patient populations. One retrospective study indicated
